7th TB-PK workshop_presentations

Clinical Pharmacology for Pediatric TB
S. Nachman
Pharmacokinetics of rifampicin, isoniazid and pyrazinamide in children on 2010 WHO/IUATLD guideline doses
H. McIlleron
A simultaneous population pharmacokinetic analysis in Malawian adults and children of rifampicin
A. Schipani
Pharmacokinetics of rifampin among pregnant women with tuberculosis and HIV co-infection
K. Dooley
Critical Path to TB regimens; Multidisciplinary / Multipartner approach
K. Romero
Drug-drug interactions between bedaquiline and the antiretrovirals nevirapine and lopinavir/ritonavir in patients
M. Pandie
High dose rifampicin: a phase II trial comparing 10, 15 and 20 mg/kg rifampicin for two months
R. Aarnoutse
Population pharmacokinetics and bacterial dynamics of sutezolid in patients with active tuberculosis
K.B. Larson
The inhibitory potential of TB drugs on ATP-binding cassette transporters MRP1-5, P-gp, BCRP and BSEP
L. Te Brake
Pharmacological knowledge gaps TB meningitis
G. Thwaites
A quantitative and systems pharmacology approach to dose optimization in experimental tuberculosis: opportunities and experimental data needs
M. Lyons
A semi mechanistic pharmacokinetic-pharmacodynamic template model for studying antitubercular drug effects in vitro
O. Clewe
Pharmacokinetics of levofloxacin in M(X)DR tuberculosis patients
N. van't Boveneind-Vrubleuskaya
Inhaled Therapy for TB
E. Nardell
Intra cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis
R. Kempker
Anti-Tuberculosis Activity of Pyrazinamide Varies by Lesion Type in C3heb/Fej Mice
J-P. Lanoix
Real-time and non-invasive, multi-compartment pharmacokinetics of 11c-rifampin in mycobacterium tuberculosis infected mice using dynamic positron emission tomography
V.P. DeMarco
Computational pharmacology of rifampin in mice: an application to dose optimization with conflicting objectives in tuberculosis treatment
M. Lyons